PF-ILD accompanying disease refers to a suspicious disease in the area of infectious respiratory digestion and endocrine disorders, with clinical performance that is complex and often involves multi-systematic stress. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
A platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of PF-ILD accompanying fingerprints requires individualized development, usually including multidimensional management of prognosis, including drug therapy, rehabilitation, regular follow-up, etc. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of the PF-ILD fingerprint. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.